Fresenius Sells Fresenius Medical Care Stake for $1.15 Billion: A Strategic Move for Long-Term Growth

Fresenius SE & Co. KGaA, a leading global healthcare company, has announced its intention to sell a significant stake in Fresenius Medical Care AG (FME) for approximately $1.15 billion. The transaction, which involves the sale of around 10.5 million shares and the issuance of exchangeable bonds with a similar underlying amount, is a strategic move aimed at strengthening Fresenius' balance sheet, reducing leverage, and driving long-term growth.

The proceeds from the sale will be allocated in line with Fresenius' #FutureFresenius strategy, focusing on balance sheet strength, reduced leverage, and delivering long-term growth and shareholder value. By retaining at least 25% plus one share of FME, Fresenius demonstrates its commitment to remaining a significant shareholder and supporting the management board through its representatives on the supervisory board of FME.



This strategic move aligns with Fresenius' long-term growth strategy, which focuses on portfolio focus, therapy expansion, and increased flexibility. By selling its stake in FME, Fresenius can redirect its investments towards its core businesses, Fresenius Kabi and Fresenius Helios, and expand its focus on therapy platforms, including (Bio)Pharma, MedTech, and Care Provision. This will enable Fresenius to cater to major trends in healthcare and become a more therapy-focused company.

The transaction is expected to have a positive impact on Fresenius' balance sheet, leverage, and financial profile, enabling the company to invest in future growth opportunities while maintaining its commitment to long-term sustainable value creation. With a stronger balance sheet and improved financial profile, Fresenius will be better positioned to pursue strategic acquisitions, expand its core businesses, and enter new markets.

In conclusion, Fresenius' decision to sell its stake in Fresenius Medical Care AG is a strategic move that aligns with its long-term growth strategy. By strengthening its balance sheet, reducing leverage, and focusing on its core businesses, Fresenius is well-positioned to continue driving growth and creating value for shareholders.